Long-Term Efficacy and Safety of Sparsentan in Young Patients With FSGS: 240-Week Analysis of the DUET Open-Label Extension (OLE)
Sparsetan Reduces Proteinuria in Patients with Immunoglobulin A Nephropathy (IgAN): Interim Results of the PROTECT Study
Preliminary Findings From the Phase 2 EPPIK Study of Sparsentan in Pediatric Patients With Selected Proteinuric Glomerular Diseases
Sparsentan receptor occupancy modeling, clinical actions, and safety
Sparsentan as First-Line Treatment of Incident Patients with IgA Nephropathy: Preliminary Findings from the SPARTAN Trial
Long-Term Efficacy and Safety of Sparsentan in Young Patients With FSGS: 240-Week Analysis of the DUET Open-Label Extension (OLE)
Sparsentan Publications 2023
IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study
SPARTAN (Phase 2 Study): Sparsentan as First-Line Therapy in the Treatment of IgA Nephropathy
SPARTACUS (Phase 2 Study): Sparsentan in Combination With SGLT2 Inhibitors Study Design
EPPIK (Phase 2 Study): Treatment in Pediatric Patients With Proteinuric Glomerular Diseases
FILSPARI (sparsentan) – PROTECT (Phase 3 Study): Study Design & Results
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis